Hormone News and Research

RSS

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to alter cell metabolism. It is essentially a chemical messenger that transports a signal from one cell to another.

Researchers uncover novel genetic markers for diabetes-related traits

In two major studies published in Nature Genetics today, researchers use biological understanding to dissect the genetics of diabetes. An international team comprising researchers from more than 100 institutions analysed vast suites of genetic data from more than 100,000 people of European descent to uncover the associations.

18 Jan 2010

JDRF and Animas partner to develop an automated system for better control of type 1 diabetes

The Juvenile Diabetes Research Foundation today announced an innovative partnership with Animas Corporation to develop an automated system to help people with type 1 diabetes better control their disease -- the first step on the path to what would be among the most revolutionary advancements in treating type 1 diabetes: the development of an artificial pancreas, a fully automated system to dispense insulin to patients based on real-time changes in blood sugar levels.

18 Jan 2010

New findings may yield novel therapies for chronic neurodegenerative diseases

We all have at one time or another experienced the typical signs of an infection: the fever, the listlessness, the lack of appetite. They are orchestrated by the brain in response to circulating cytokines, the signaling molecules of the immune system. But just how cytokines' reach extends beyond the almost impenetrable blood-brain barrier has been the topic of much dispute.

18 Jan 2010

Androgen replacement therapy may ward off heart damage, says study

A man's male hormones may ward off heart damage by helping vessels around the heart regenerate, suggest Australian researchers in a report posted January 13 in the Journal of Experimental Medicine (www.jem.org).

18 Jan 2010

AACE sends petition to Congress opposing new Medicare policy

The American Association of Clinical Endocrinologists (AACE) sent a petition to Congress today signed by 1,325 AACE members, non-AACE member physicians, allied health professionals and patients opposing a new Medicare policy which would eliminate consultation codes for specialists.

13 Jan 2010

Growth hormone deficiency can lead to memory deficits later in life

Scientists have shown that early growth hormone supplementation in rats with growth hormone deficiency can prevent defects in memory developing later in adulthood. The study, published in the Journal of Endocrinology is the first to show that memory defects in adults as a result of growth hormone deficiency arising in childhood can be prevented by growth hormone treatment during adolescence.

13 Jan 2010

New analysis finds cost of diabetes and pre-diabetes reached $218 billion in 2007

A new analysis found that the cost of diabetes and pre-diabetes reached $218 billion in 2007, with the exploding number of cases of type 2 diabetes responsible for the majority of the costs. The National Changing Diabetes® Program (NCDP), a program of Novo Nordisk, commissioned the analysis, published online as a Web First article today in Health Affairs and performed by researchers at The Lewin Group.

13 Jan 2010

Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1

Emisphere Technologies, Inc. today announced that Novo Nordisk has initiated its first Phase I clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a $2 million payment to Emisphere, whose proprietary Eligen® Technology is used in the formulation of NN9924.

13 Jan 2010

New clinical study: CeNeRx BioPharma's CXB722 has potential as novel anxiolytic

CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today reported that a new clinical study shows that its investigational compound CXB722 has potential as a novel anxiolytic, demonstrating a significant effect on both endocrine and cardiovascular biomarkers associated with stress.

13 Jan 2010

NeuroScience launches NEI Guided Nutrition Program

NeuroScience, Inc. has launched a comprehensive and customizable dietary program based on patients' food sensitivity test results. The NEI Guided Nutrition Program(TM) is the first offering through NeuroScience, Inc.'s new NEI Nutrition(TM) division.

12 Jan 2010

Salt Lake City research center joins international drug trial program for painful menstrual cramps

A leading clinical research center in Salt Lake City has joined an international trial program to test an experimental new drug designed to treat painful menstrual cramps, or dysmenorrhea, a condition that affects between 45 and 90 percent of women of childbearing age in the United States. Although not life threatening, dysmenorrhea can be debilitating and psychologically taxing and is one of the leading causes of absenteeism from work and school.

12 Jan 2010

Multigene test results impact physicians and patients' decisions on breast cancer therapy

A 21-gene test that predicts whether early stage breast cancer patients will benefit from chemotherapy is having a big impact on treatment decisions by patients and doctors alike.

12 Jan 2010

Researchers study VA111913 drug as a possible treatment for dysmenorrhea

A leading clinical research center in Austin has joined an international research program to study an investigational drug designed as a possible treatment for painful menstrual cramps, or dysmenorrhea, a condition that affects between 45 and 90 percent of women of childbearing age in the United States.

12 Jan 2010

Antares Pharma, Population Council report positive Phase 2 results for novel NES/E2 contraceptive gel

Antares Pharma, Inc. and the Population Council today announced successful results from a dose-finding Phase 2 trial for a novel contraceptive gel containing the progestin Nestorone and estradiol (NES/E2) utilizing the Antares ATD (advanced transdermal delivery) gel system. Based on this successful data, the two parties continue to expect to partner with a worldwide or regional pharmaceutical company in order to commercialize this novel contraceptive gel.

12 Jan 2010

Exercise may improve cognitive function

Moderate physical activity performed in midlife or later appears to be associated with a reduced risk of mild cognitive impairment, whereas a six-month high-intensity aerobic exercise program may improve cognitive function in individuals who already have the condition, according to two reports in the January issue of Archives of Neurology, one of the JAMA/Archives journals.

11 Jan 2010

Immune cells causes inflammation in thyroid-associated ophthalmopathy

A cell type that causes significant scarring in lung disease appears to have a similar effect in Graves' disease, University of Michigan Health System researchers have found. The cells, called fibrocytes, are present at a higher than normal frequency in patients with Graves' disease, according to a new study, the first to associate fibrocytes with this autoimmune disease.

9 Jan 2010

Fibrocytes associated with Graves' disease

9 Jan 2010

A holistic approach to weight loss

When your New Year's resolution to lose weight crumbles as fast as the cookie touching your lips, it's time to admit that diets don't work. More successful is a holistic approach to losing weight that lets you feel good about feeding your body the nourishment it craves.

8 Jan 2010

Aneeve Nanotechnologies selected to work in the UCLA on-campus Technology Incubator Program

Aneeve Nanotechnologies LLC has been selected to work in the UCLA on-campus Technology Incubator Program at the California NanoSystems Institute. The startup company will conduct early-stage research for the development of a novel hormone sensor/meter for biomedical applications in the areas of infertility and menopause.

8 Jan 2010

Ligand Pharmaceuticals receives $1 million as payment from N. V. Organon

Ligand Pharmaceuticals Incorporated announced today that it has received a $1 million milestone payment from N. V. Organon, a subsidiary of Merck & Co., Inc., stemming from its research collaboration that expired on December 31, 2009.

8 Jan 2010

Hormone News and Research

Further Reading

Researchers uncover novel genetic markers for diabetes-related traits

JDRF and Animas partner to develop an automated system for better control of type 1 diabetes

New findings may yield novel therapies for chronic neurodegenerative diseases

Androgen replacement therapy may ward off heart damage, says study

AACE sends petition to Congress opposing new Medicare policy

Growth hormone deficiency can lead to memory deficits later in life

New analysis finds cost of diabetes and pre-diabetes reached $218 billion in 2007

Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1

New clinical study: CeNeRx BioPharma's CXB722 has potential as novel anxiolytic

NeuroScience launches NEI Guided Nutrition Program

Salt Lake City research center joins international drug trial program for painful menstrual cramps

Multigene test results impact physicians and patients' decisions on breast cancer therapy

Researchers study VA111913 drug as a possible treatment for dysmenorrhea

Antares Pharma, Population Council report positive Phase 2 results for novel NES/E2 contraceptive gel

Exercise may improve cognitive function

Immune cells causes inflammation in thyroid-associated ophthalmopathy

Fibrocytes associated with Graves' disease

A holistic approach to weight loss

Aneeve Nanotechnologies selected to work in the UCLA on-campus Technology Incubator Program

Ligand Pharmaceuticals receives $1 million as payment from N. V. Organon

Viva Saliva Book: The ultimate guide to saliva Book preview Download eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News